A detailed history of Group One Trading, L.P. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Group One Trading, L.P. holds 9,289 shares of URGN stock, worth $113,697. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,289
Holding current value
$113,697
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$12.72 - $19.2 $118,156 - $178,348
9,289 New
9,289 $155,000
Q4 2023

Feb 14, 2024

BUY
$10.87 - $15.93 $1,087 - $1,593
100 New
100 $1,000
Q1 2022

May 12, 2022

SELL
$5.92 - $9.73 $83,093 - $136,570
-14,036 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$9.03 - $19.13 $267,215 - $566,094
-29,592 Reduced 67.83%
14,036 $133,000
Q3 2021

Nov 12, 2021

SELL
$14.31 - $18.39 $130,879 - $168,194
-9,146 Reduced 17.33%
43,628 $734,000
Q2 2021

Aug 10, 2021

SELL
$15.2 - $20.94 $544,540 - $750,175
-35,825 Reduced 40.43%
52,774 $806,000
Q1 2021

May 12, 2021

SELL
$17.99 - $26.96 $740,144 - $1.11 Million
-41,142 Reduced 31.71%
88,599 $1.73 Million
Q4 2020

Feb 10, 2021

SELL
$17.54 - $25.43 $441,464 - $640,047
-25,169 Reduced 16.25%
129,741 $2.34 Million
Q3 2020

Nov 12, 2020

BUY
$18.81 - $26.42 $1.69 Million - $2.38 Million
90,038 Added 138.79%
154,910 $2.99 Million
Q2 2020

Aug 13, 2020

BUY
$16.5 - $29.7 $708,345 - $1.28 Million
42,930 Added 195.65%
64,872 $1.69 Million
Q1 2020

May 13, 2020

SELL
$13.68 - $34.6 $84,186 - $212,928
-6,154 Reduced 21.9%
21,942 $391,000
Q4 2019

Feb 10, 2020

BUY
$21.11 - $34.86 $593,106 - $979,426
28,096 New
28,096 $938,000
Q4 2018

Feb 06, 2019

SELL
$38.35 - $50.39 $6,903 - $9,070
-180 Closed
0 $0
Q3 2018

Nov 08, 2018

BUY
$41.65 - $51.7 $7,497 - $9,306
180 New
180 $9,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $278M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.